Covid 19 Research using Clinical Trials (Home Page)
Report for D000077299: Healthcare-Associated Pneumonia NIH
(Synonyms: Healthcare-Associated Pneumonia)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug986 | Elisa-test for IgM and IgG to SARS-CoV-2 Wiki | 0.71 |
| drug1381 | IgM and IgG diagnostic kits to SARS-CoV-2 Wiki | 0.71 |
There are 2 clinical trials
Clinical Trials
1 The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia
The purpose of the study is to determine if the clinical course of pneumonia is more severe when both, bacterial and viral pathogens are find as possible causative agent and how does it affect treatment.
NCT02203110 Community Acquired Pneumonia Hospital Acquired Pneumonia Ventilator Associated Pneumonia MeSH:Pneumonia, Ventilator-Associated Healthcare-Associated Pneumonia Pneumonia
HPO:Pneumonia
Primary Outcomes
Measure: Rate of changes in empirical antibiotic therapy due to broad microbiological diagnostic Time: each patient will be assessed at enrollment and follow-up for 2 months
2 Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia: COVAP Study
Primary Outcomes
Measure: Rate of changes in empirical antibiotic therapy due to broad microbiological diagnostic Time: each patient will be assessed at enrollment and follow-up for 2 monthsA Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation. In the most severe forms, it may require mechanical ventilation or even lead to an acute respiratory distress syndrome with a particularly poor prognosis. The SARS-CoV2 is a single-stranded RNA virus of positive polarity and belongs to the beta genus of Coronaviruses. SARS-CoV2 is responsible for the third epidemic in less than twenty years secondary to a Coronavirus (SARS-CoV then MERS-CoV) and if the mortality associated with it is lower than that of previous strains, notably MERS-CoV, its spread is considerably big. As a result, the number of patients developing respiratory distress requiring invasive mechanical ventilation is high, with prolonged ventilation duration in these situations
NCT04488510 Covid19 Ventilator Associated Pneumonia Nosocomial Pneumonia MeSH:Pneumonia, Ventilator-Associated Healthcare-Associated Pneumonia Coinfection Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: Establishing a biobank of the bacterial agents responsible for nosocomial pneumonia acquired under mechanical ventilation in order to: better understand the particularities of the bacteria responsible and obtain the "clinical" strains for in vitro studies that will be carried out secondarily.
Measure: Research of the bacteria responsible for nosocomial pneumonia Time: 6 months
Secondary Outcomes
Description: Evaluation of the adhesion properties to the bronchial epithelium (LPS peculiarities of Gram-negative bacteria, the interaction with the virus in in vitro models and the different molecules of interest in the collected bronchial secretions).
Measure: Additional evaluations to the study Time: 6 months
HPO Nodes
Primary Outcomes
Description: Establishing a biobank of the bacterial agents responsible for nosocomial pneumonia acquired under mechanical ventilation in order to: better understand the particularities of the bacteria responsible and obtain the "clinical" strains for in vitro studies that will be carried out secondarily.
Measure: Research of the bacteria responsible for nosocomial pneumonia Time: 6 monthsSecondary Outcomes
Description: Evaluation of the adhesion properties to the bronchial epithelium (LPS peculiarities of Gram-negative bacteria, the interaction with the virus in in vitro models and the different molecules of interest in the collected bronchial secretions).
Measure: Additional evaluations to the study Time: 6 months